These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9049571)

  • 21. Secondary prevention after myocardial infarction.
    Evans AE
    Lancet; 1986 Jul; 2(8499):150-1. PubMed ID: 2873409
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease.
    Meurice T; Tricot O; Lemesle G; Deneve M; Lejeune P; Biausque F; Cordier C; Savoye C; Hennebert O; Taghipour K; Sivery B; Pruvost P; Alaoui M; Carpentier L; Segrestin B; Lamblin N; Bauters C
    Arch Cardiovasc Dis; 2015; 108(6-7):340-6. PubMed ID: 25858539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of myocardial reinfarction. Recommendations based on results of drug trials.
    Flaker GC; Singh VN
    Postgrad Med; 1993 Nov; 94(6):94-8, 102-4. PubMed ID: 7901845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction.
    Goodman S; Hill C; Bata I; Fung A; Higginson L; Lam J; Massel D; McCans J; Nasmith J; Stanton E; Thompson C; Warnica W; Langer A
    Can J Cardiol; 1996 Nov; 12(11):1183-90. PubMed ID: 9191511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital.
    Mitra S; Findley K; Frohnapple D; Mehta JL
    Clin Cardiol; 2002 Jan; 25(1):16-8. PubMed ID: 11808833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Secondary prevention of ischemic heart disease: pharmacological treatment after myocardial infarction according to follow-up protocol].
    Milvidaite I; Luksiene D; Slapikiene B; Babarskiene MR; Liukaitis V; Maciulaitis R; Kadusevicius E; Pilviniene R
    Medicina (Kaunas); 2007; 43(2):131-6. PubMed ID: 17329948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of the patient with infarction after hospital discharge (Consensus about post-myocardial infarction treatment)].
    Arq Bras Cardiol; 1995 Mar; 64(3):281-8. PubMed ID: 7487520
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.
    Lindholm LH; Hansson L; Ekbom T; Dahlöf B; Lanke J; Linjer E; Scherstén B; Wester PO; Hedner T; de Faire U
    J Hypertens; 2000 Nov; 18(11):1671-5. PubMed ID: 11081782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial.
    Barzi F; Woodward M; Marfisi RM; Tavazzi L; Valagussa F; Marchioli R;
    Eur J Clin Nutr; 2003 Apr; 57(4):604-11. PubMed ID: 12700623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do intensive blood pressure lowering and low-dose ASA help our hypertensive patients?
    Evans MF
    Can Fam Physician; 1998 Dec; 44():2655-7. PubMed ID: 9870118
    [No Abstract]   [Full Text] [Related]  

  • 33. Quality of ambulatory care after myocardial infarction among Medicare patients by type of insurance and region.
    Seddon ME; Ayanian JZ; Landrum MB; Cleary PD; Peterson EA; Gahart MT; McNeil BJ
    Am J Med; 2001 Jul; 111(1):24-32. PubMed ID: 11448657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Secondary prevention in chronic coronary heart disease].
    Hunziker P; Bertel O
    Schweiz Med Wochenschr; 1997 Feb; 127(7):254-60. PubMed ID: 9157530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beta-blockers for hypertension.
    Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol.
    Itsiopoulos C; Kucianski T; Mayr HL; van Gaal WJ; Martinez-Gonzalez MA; Vally H; Kingsley M; Kouris-Blazos A; Radcliffe J; Segal L; Brazionis L; Salim A; Tierney AC; O'Dea K; Wilson A; Thomas CJ
    Am Heart J; 2018 Sep; 203():4-11. PubMed ID: 29966802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction.
    Aronow WS; Ahn C; Kronzon I
    Am J Cardiol; 2001 Dec; 88(11):1298-300. PubMed ID: 11728359
    [No Abstract]   [Full Text] [Related]  

  • 38. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    Lindahl B; Baron T; Erlinge D; Hadziosmanovic N; Nordenskjöld A; Gard A; Jernberg T
    Circulation; 2017 Apr; 135(16):1481-1489. PubMed ID: 28179398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
    Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home.
    Ghosh S; Ziesmer V; Aronow WS
    J Gerontol A Biol Sci Med Sci; 2002 Jun; 57(6):M398-400. PubMed ID: 12023270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.